Discover the art of histopathology through the eyes of our most skilled scientists.
Immunohistochemistry biomarkers are key players in clinical development success. Tissue biomarkers can aid in the confirmation of diagnosis, patient selection, and/or for mechanistic evaluation.
If you would like to know more about how Cerba Research can help you, our IHC expert scientific team will consult with you on your specific needs. Flexible in our approach and delivery to provide timely and cost effective solutions to meet your clinical and commercial objectives.
Download our digital book to see the art of histopathology for yourself.
Webinar – Turning Precision Medicine Into Action in Immuno-Oncology
The challenges in immuno-oncology (I/O) drug development require deep scientific insights, generation and analysis of complex biological data, new state-of-the art technologies and both logistical & operational support across continents. The goal of immuno-oncology drug developers is to turn precision medicine into action, bringing life-changing therapies to patients.
In this webinar our experts discuss the use of Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Flow Cytometry (FCM) within immuno-oncology, and how they can offer the comprehensive insights required for I/O clinical trials.
Speakers
Jérôme Sallette, PhD, CSO Cerba Research
Shu Jen Chen, PhD, CSO ACT Genomics
Sofie Vandevyver, PhD, Head of Business Operations & Marketing Cerba Research
George Wei, PhD, Vice President R&D ACT Genomics
Renaud Burrer, PhD, Head of Histopathology Cerba Research
Nithianandan Selliah, PhD, Global Head Flow Cytometry Cerba Research
Webinar – Advantages And Versatility Of Flow Cytometry Considerations For Clinical Trial Speciality Lab Outsourcing
It is now clear that the therapeutic future lies in biomarkers through the development of immunotherapies and companion diagnostics. Among the techniques of biomarker analysis, there is Flowcytometry, which allows for precise analysis of liquid samples, but not only.
Validation test development for specific biomarkers is a prerequisite for a successful application in translational research, preclinical and clinical phases. The advantages and disadvantages of this technique, the samples, and the conditions of use: Cerba Research will open the doors of its worldwide laboratories for an hour. To answer all your questions about one of the leading techniques of analysis for the development of innovative treatments, our experts will share their knowledge and experience.
Nithianandan Selliah, Ph.D., Global Head of Flow Cytometry at Cerba Research
Nithianandan obtained his PhD in Immunology and started to work on HIV research. After more than 10 years of HIV research, he joined a biotech company to work on biomarker discovery for autoimmune diseases. His interest in Flow cytometry at the biotech company led him to join global CRO to work on assay development and validation in Flow cytometry for global clinical trials. He joined Cerba Research to continue to work on his passion for Flow cytometry in clinical trial and takes on new challenges to build the best Flow cytometry service to the clients.
He is working with exceptional scientific teams in the US and Belgium to bring on new assays for various therapeutic indications, including Immuno-oncology and autoimmune diseases.
Ishita Modi, Director, Scientific Customer Solutions at Cerba Research
A microbiologist by education, Ishita finished her studies at Gujarat University in India and moved on to start her career in the United States. She has more than 15 years of experience in the clinical and diagnostic research industry. Her expertise is in building a strong foundation of clinical operations and clinical research with a commitment to meeting client’s scientific needs to help advance medicine. Ishita has worked at CRO/Central Lab as well as at some of the leading clinical diagnostic labs in the region. Her scientific expertise includes infectious diseases and genetics, and gained extensive experience in microbiology, virology, and molecular biology. Ishita is a New York State-certified Medical Technologist and also a certified IRB (Institutional Review Board) professional. Her experience over the years has made her very strong in all aspects of clinical research and regulatory requirements. She has a passion for advancing science and making a difference in the future of healthcare.
Webinar – Advantages and Versatility of Flow Cytometry Considerations for Clinical trial Speciality Lab Outsourcing
Reach out to our experts to see how we can help advance your clinical trial
Webinar – Conducting Clinical Trials During COVID-19: Lessons For The Next Pandemic
The coronavirus is not the first infectious disease that has forced clinical trials to adapt. Zika, Ebola and other diseases called for the world to adjust and collaborate global research efforts. With COVID-19, the rapid spread and impact on global healthcare systems forced us to change our trial management and accelerate our processes like never before. The global research community have already discovered and developed several tests and vaccines in record time through collaboration. Yet we are still working on predictive biomarker testing to identify people who are at the most risk of developing severe symptoms, epidemiological, vaccine and genetic studies.
To facilitate testing, research, and innovation and to ensure trials continued, Cerba Research and Cerba Healthcare adapted our capabilities and facilities to push research continuity.
Watch this webinar and discover the answers to these questions:
Did we succeed, how fast did we adapt and are we ready to face a new pandemic crisis in the future?
How did we maintain the high security and confidence of testing, and what did our reactivity and proactivity mean in the context of a health crisis?
Webinar – Conducting Clinical Trials During COVID-19 Lessons for the Next Pandemic
Reach out to our experts and discover how we can help you advance your clinical trial
Webinar – Biomarkers In Immuno-Oncology: Identifying And Implementing Biomarker Testing From Exploratory Research To Clinical Trials
Biomarkers are at the heart of Immuno-Oncology. In this webinar, we will walk you through three case studies to highlight the importance of biomarkers, using different methodologies. Why do some patients respond better to I/O therapeutics than others? What is Flow Cytometry’s role in immunophenotyping? Where does Immunohistochemistry come in? What is the Tumor Mutation Burden, how does it impact I/O research?
Amanda Finan, Head of IHC R&D Cerba Research, Nithianandan Selliah, Global Head of Flow Cytometry Cerba Research, and Raouf Ben Abdelali, Head of the Hematology and Oncology Division, Cerba Laboratory will guide you through their respective fields of expertise and answer the above questions.
Biomarkers in Immuno Oncology: Identifying and Implementing Biomarker Testing
Reach out to our experts and discover how we can help you advance your clinical trial
Discover how our experts helped our sponsor set up a randomized, open-label, multicentre Phase 3 study to compare progression-free survival upon two different combination therapies (with a targeted MoA) in patients with relapsed or refractory multiple myeloma.
See how we were able to handle:
aggressive study timelines
frequent changes to the protocol
the adding CD138+, FISH, and cell clonality added after the study started
Japan added as a separate study later as well
the sponsor monitored TAT closely and wanted centralized genomics testing and aggregate reporting.
Poster – Immune Cell Checkpoint Profiling Of Solid Tumors By Multiplex Immunofluorescence
Immune checkpoint proteins are important regulators in self-tolerance but also allow cancer cells to evade immune destruction. Checkpoint inhibitor (CKI) blockade therapies can help restore antitumoral immunity. Combination blockade has demonstrated the potential to result in greater tumor growth inhibition than monotherapies in preclinical studies.
Multiplex immunofluorescence offers a technical advantage by allowing for the detection of co-expression and spatial organization of multiple targets within a preserved tissue architecture on a single slide. We have developed the HISTOPROFILE®-CKI multiplex immunohistochemistry panel to offer personalized immune cell checkpoint profiling.
Poster – Immune cell checkpoint profiling of solid tumors by multiplex immunofluorescence
Fact Sheet – NASH Clinical Trials – Supporting The Biggest Phase 3 Study In NASH
In a meta-analysis of several studies using various methodologies, worldwide prevalence of NAFLD (Non-alcoholic fatty liver disease) is 25.2% and 6.45% for NASH (Non-Alcoholic SteatoHepatitis). NASH prevalence is expected to increase by 63% between 2015 and 2030, yet the condition is still poorly understood and there is no known treatment. The need for therapeutic agents is urgent.
At Cerba Research, we are committed to improving the diagnosis and treatment for NASH. In 2016, after we successfully supported their Phase II NASH study, a midsize biotech engaged our services for Phase III. Gratified to have gained their trust and eager to continue our productive collaboration with this meticulous client, we rolled up our sleeves and took on the challenge of supporting the largest NASH Phase III study to date.
Discover how Cerba Research was able to support one of the biggest Phase 3 studies in NASH
NASH Clinical Trials – Supporting the biggest phase 3 study in NASH
Fact Sheet – Unveiling the Oncology Journey: Highlighting Cutting-Edge Capabilities
Cerba Research has conducted nearly 200 oncology trials within the last 5 years alone. Its experience extends to both solid and liquid tumors and includes specialized assays such as next-generation sequencing (NGS), flow cytometry (FCM), immunohistochemistry (IHC), and NanoString®. Check our latest fact sheet to learn more about our highlights and capabilities.
Resource Library
